G-CSF 930101 Study Group AIDS 1998; 12: 65–74 41 Kuritzkes DR

G-CSF 930101 Study Group. AIDS 1998; 12: 65–74. 41 Kuritzkes DR. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating

factor. Clin Infect Dis 2000; 30: 256–260. 42 Tomblyn M, Chiller T, Einsele H et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15: 1143–1238. 43 Freifeld AG, Bow EJ, Sepkowitz KA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect www.selleckchem.com/products/pexidartinib-plx3397.html Dis 2011; 52: e56–93. 44 Cullen M, Steven N, Billingham L et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005; 353: 988–998. 45 Engels EA, Lau Ku-0059436 J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998; 16: 1179–1187. 46 Baden LR. Prophylactic antimicrobial

agents and the importance of fitness. N Engl J Med 2005; 353: 1052–1054. 47 Flowers CR, Seidenfeld J, Bow EJ et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013; 31: 794–810. 48 Saral R, Burns WH, Laskin OL et al. Acyclovir

prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981; 305: 63–67. 49 Saral R, Ambinder RF, Burns WH et al. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled oxyclozanide study. Ann Intern Med 1983; 99: 773–776. 50 Boeckh M, Kim HW, Flowers ME et al. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation–a randomized double-blind placebo-controlled study. Blood 2006; 107: 1800–1805. 51 Centers for Disease Control and Prevention; Infectious Disease Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000; 49(RR-10): 1–125 CE121–127. 52 Einsele H, Ehninger G, Hebart H et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815–2820. 53 Boeckh M, Gooley TA, Myerson D et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063–4071. 54 Beck CR, McKenzie BC, Hashim AB et al.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>